Alzheimer´s drugs rejected for NHS because benefits...

4 months ago 6

The National Institute for Health and Care Excellence is standing by its earlier decision to turn down donanemab and lecanemab after considering new information.

Source: https://www.dailymail.co.uk/health/article-14826837/Alzheimer-s-drugs-rejected-NHS-benefits-small-justify-cost.html?ns_mchannel=rss&ito=1490&ns_campaign=1490

Read Entire Article

Disclaimer of liability !!!

NEWS.SP1.RO is an automatic news aggregator. In each article, taken over by NEWS.SP1.RO with maximum 500 characters from the original article, the source name and hyperlink to the source are specified.

The acquisition of information aims to promote and facilitate access to information, in compliance with intellectual property rights, in accordance with the terms and conditions of the source.

If you are the owner of the content and do not wish to publish your materials, please contact us by email at [email protected] and the content will be deleted as soon as possible.